Palbociclib

Overview

Palbociclib is a selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor used in the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. It works by interfering with the growth and division of cancer cells.

API suppliers (3)

Suppliers of Palbociclib backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• MATRIX PHARMACORP PRIVATE LTD1 active DMF
• Apotex Inc.Canada1 active DMF
• MSN Laboratories Private LimitedIndia1 active DMF

Patent & exclusivity (US)

Per the FDA Orange Book (6 approved US products), the latest listed US patent on Palbociclib expires 19 Feb 2037 and exclusivity 16 Mar 2029. Generic API sourcing typically opens up once these lapse.

Therapeutic areas